Autolus Announces Appointment of Edgar Braendle, M.D., Ph.D., as Chief Development Officer
15 juil. 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, July 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Report Second Quarter 2021 Financial Results on August 5, 2021, and will Participate in the William Blair Biotech Focus Conference 2021 on July 14, 2021
08 juil. 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, July 08, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Announces Innovation Licensing and Access Pathway (ILAP) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL
15 juin 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, June 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Presents New Data on obe-cel in r/r Indolent B Cell Lymphomas and gives an update of obe-cel in r/r Adult ALL at the European Hematology Association Virtual Congress
11 juin 2021 07h00 HE
|
Autolus Therapeutics plc
Obe-cel achieves 100% complete remission rate in a cohort of indolent B Cell Non-Hodgkin lymphoma patients with excellent CAR T engraftment, expansion, and persistence No ICANS or high grade...
Autolus Therapeutics Announces an Additional Nature Publication for AUTO1
25 mai 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, May 25, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a...
Autolus Notice of Annual General Meeting (AGM) on Friday, June 18, 2021
21 mai 2021 07h00 HE
|
Autolus Therapeutics plc
Attendance in person is not permitted LONDON, May 21, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation...
Autolus Therapeutics to Present New Data on AUTO1 in r/r Indolent B Cell Lymphomas at the European Hematology Association Virtual Congress
12 mai 2021 10h00 HE
|
Autolus Therapeutics plc
AUTO1 achieves 100% complete remission rate in cohort of r/r Indolent Non- Hodgkin Lymphoma patients No high-grade cytokine release syndrome or neurotoxicity observed LONDON, May 12, 2021 ...
Autolus Therapeutics Reports First Quarter 2021 Financial Results and Operational Progress
06 mai 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, May 06, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Report First Quarter 2021 Financial Results and Host Conference Call on May 6
26 avr. 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, April 26, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics announces appointment of Martin Murphy as Non-executive Chairman
19 avr. 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, April 19, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...